Education
About Us
Working with TipRanks
Follow Us
Renalytix (RNLXD)
OTHER OTC:RNLXD
RNLXD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
RNLXD FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest stock price was $3.13 and its highest was $8.10 in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is $34.62M.
When is Renalytix’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Renalytix’s earnings last quarter?
Currently, no data Available
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Undervalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 8,740,374 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in RNLXD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Renalytix
Renalytix (RNLXY) is a healthcare technology company focused on developing and commercializing diagnostic solutions for kidney disease. The company operates within the biotechnology and medical device sectors, offering innovative products and services designed to improve kidney health management and patient outcomes. Renalytix combines advanced diagnostics with machine learning to provide actionable insights for healthcare providers, aiming to enhance the early detection and treatment of kidney disease.
Ownership Overview
―
Insiders
―
Mutual Funds
― Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---